ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
Profile of Serum Bile Acids in Elderly Type 2 Diabetic Patients with Various Obesity Types: A Cross-Sectional Study.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lithocholic Acid Restores Gut Microbiota and Bile Acid Homeostasis to Improve Type 2 Diabetes.Nutrients · 2026Article
- Pharmacomicrobiomics in metabolic syndrome and type 2 diabetes: the microbiome-drug-host triad.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The distribution of body fat plays a critical role in the pathogenesis of type 2 diabetes mellitus (T2DM). However, the specific metabolic profiles and biomarkers that distinguish the different obesity phenotypes in T2DM remain to be fully elucidated. Bile acids (BAs), which are recognized as pivotal signaling molecules in the regulation of glucose and lipid metabolism, warrant further investigation to characterize their profiles across different obesity phenotypes. Understanding the clinical significance of these BAs in the management of T2DM is essential and merits thorough exploration. Design: In this cross-sectional study conducted at the Zhangjiang Community Health Service Center in Shanghai, ninety-nine elderly participants were recruited and categorized into four groups: non-diabetic controls (NC), T2DM with lean phenotype (TN), T2DM with overweight phenotype (TO), and T2DM with abdominal obesity phenotype (TA). Biochemical indices, visceral adiposity indices, and bile acid (BA) profiles were analyzed and compared across the groups. Results: Healthy individuals exhibited lower triglyceride levels, waist-to-hip ratio (WHR), visceral adiposity index (VAI), and Chinese visceral adiposity index (CVAI), as well as higher HDL-c level and total BA levels compared to T2DM patients. T2DM patients with different obesity phenotypes displayed distinct BA profiles. Specifically, the TN group showed higher levels of conjugated DCA BA species, GDCA, and TDCA, compared to the TO group. These BA species are essential for regulating lipid and glucose metabolism. In contrast, the TA group exhibited higher ratios of 12α-hydroxylated BAs to non 12α-hydroxylated BAs, taurine-conjugated BAs to glycine-conjugated BAs, and higher levels of LCA compared to the TO group. Additionally, CVAI was positively associated with unconjugated SBAs, CA-7S, and DLCA. Conclusion: These results revealed that T2DM patients with different obesity phenotypes exhibit distinct BA profiles. Specific BAs, particularly GDCA, TDCA, and LCA, are closely associated with adiposity indices and may serve as crucial signaling molecules in modulating visceral adiposity, serum lipid profiles, and glucose homeostasis in obese T2DM patients. These BA species play a pivotal role in the pathogenetic process underlying diabetes and various forms of obesity. Furthermore, their significance highlights their potential contributors to drug development and as therapeutic targets for T2DM patients with specific obesity subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.